Supplementary Table S5 from Phase I...

Supplementary Table S5 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma

Abstract

<p>Supplementary Table S5. Serum PK Parameters of AGS15E ADC at Cycle 1, Day 1 by Dose Group, PK Analysis Set</p>

Petrylak DP; Eigl BJ; George S; Heath EI; Hotte SJ; Chism DD; Nabell LM; Picus J; Cheng SY; Appleman LJ

January 5, 2024

10.1158/1078-0432.24947811.v1

Sebastien Hotte